Skip to content

Faeth Therapeutics, Inc.

Public company
Headquarters
AUSTIN, Texas
Ticker
FTH
CIK
0001829802

WARN notices since 2024

0
None on record

Workers affected since 2024

0
Across 0 notices

Executive changes, last 12 months

2
2 appointments, 0 departures

Last event

Oct 27, 2026
Executive appointmentClass III director appointed: Adam Schayowitz

Workers affected over time

Cumulative workers in WARN notices since 2024

Not enough notices to chart yet.

Leadership

Role and personSinceChange
Class III directorAdam SchayowitzOct 27, 2026Appointed
Class II directorKaren Vousden, Ph.D.Sep 17, 2026Appointed

Same industry and state, with recent events.

  1. Executive appointment

    Class III director appointed: Adam Schayowitz

    Adam Schayowitz was named Class III director of Faeth Therapeutics, Inc., effective October 23, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class III director

    Source: SEC 8-K, filed Oct 27, 2026
  2. Executive appointment

    Class II director appointed: Karen Vousden, Ph.D.

    Karen Vousden, Ph.D. was named Class II director of Faeth Therapeutics, Inc., effective September 11, 2026. The company reported the change in an 8-K that cites Item 5.02.

    Role: Class II director

    Source: SEC 8-K, filed Sep 17, 2026

Last verified Nov 8, 2026